Drugs / Tripegfilgrastim
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02963389 | Oct 2016 → Nov 2018 | cancer, lymphoma | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06135896 | Jan 2024 → Jun 2026 overdue | bile duct carcinoma, pancreas disorder | National Cancer Center, Korea | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tripegfilgrastim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06135896 ↗ |
| Modality | Protein / enzyme biologic | “A long-acting granulocyte colony-stimulating factor, tripegfilgrastim, was approved in Korea” PMID 34605552 ↗ Oct 2021 |
| Route | Subcutaneous | “A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy” NCT02963389 ↗ |